Ipilimumab (Yervoy) has been approved by the European Commission for the treatment of patients aged 12 and older with unresectable or metastatic melanoma.
Publications
Melanoma Journal Articles for January 2018
Ophthalmology Conjunctival amelanotic malignant melanoma arising in primary acquired melanosis sine pigmento MD Venita Jay and MD Ramon L. Font https://doi.org/10.1016/S0161-6420(98)92156-X Annals of Surgical Oncology Melanoma Surveillance Strategies: Different Approaches to…
Read More Nivolumab Earns FDA Approval as Adjuvant Therapy for Melanoma Based on Checkmate-238 Trial
According to the National Cancer Institute, about 2.2% of people will be diagnosed with melanoma at a point in their lifetime.
Ipilimumab Approaches EU Approval for Pediatric Melanoma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of ipilimumab (Yervoy) for the treatment of pediatric patients aged 12 years and older with unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.